<table>
<thead>
<tr>
<th>Title</th>
<th>The dsRBP and inactive editor ADR-1 utilizes dsRNA binding to regulate A-to-I RNA editing across the C. elegans transcriptome.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Washburn, Michael C.; Kakaradov, Boyko.; Sundararaman, Balaji.; Wheeler, Emily.; Hoon, Shawn.; Yeo, Gene W.; Hundley, Heather A.</td>
</tr>
<tr>
<td>Date</td>
<td>2014</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10220/18837">http://hdl.handle.net/10220/18837</a></td>
</tr>
<tr>
<td>Rights</td>
<td>© 2014 The Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.</td>
</tr>
</tbody>
</table>
The dsRBP and Inactive Editor ADR-1 Utilizes dsRNA Binding to Regulate A-to-I RNA Editing across the C. elegans Transcriptome

Michael C. Washburn,1,8 Boyko Kakaradov,2,3,6 Balaji Sundararaman,3 Emily Wheeler,4 Shawn Hoon,5,6 Gene W. Yeo,2,5,7,* and Heather A. Hundley4,*

1Department of Biology, Indiana University, Bloomington, IN 47405, USA
2Bioinformatics and Systems Biology Program, University of California, San Diego, La Jolla, CA 92093-0419, USA
3Department of Cellular and Molecular Medicine, UCSD Stem Cell Program and Institute for Genomic Medicine, University of California, San Diego, La Jolla, CA 92093-0651, USA
4Medical Sciences Program, Indiana University, Bloomington, IN 47405, USA
5Molecular Engineering Laboratory, A*STAR, Singapore 138673, Singapore
6School of Biological Sciences, Nanyang Technological University, Singapore 639798, Singapore
7Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore
8These authors contributed equally to this work
*Correspondence: geneyeo@ucsd.edu (G.W.Y.), hahundle@indiana.edu (H.A.H.)

http://dx.doi.org/10.1016/j.celrep.2014.01.011

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

SUMMARY

Inadequate adenosine-to-inosine editing of noncoding regions occurs in disease but is often uncorrelated with ADAR levels, underscoring the need to study deaminase-independent control of editing. C. elegans have two ADAR proteins, ADR-2 and the theoretically catalytically inactive ADR-1. Using high-throughput RNA sequencing of wild-type and adr mutant worms, we expand the repertoire of C. elegans edited transcripts over 5-fold and confirm that ADR-2 is the only active deaminase in vivo. Despite lacking deaminase function, ADR-1 affects editing of over 60 adenosines within the 3' UTRs of 16 different mRNAs. Furthermore, ADR-1 interacts directly with ADR-2 substrates, even in the absence of ADR-2, and mutations within its double-stranded RNA (dsRNA) binding domains abolish both binding and editing regulation. We conclude that ADR-1 acts as a major regulator of editing by binding ADR-2 substrates in vivo. These results raise the possibility that other dsRNA binding proteins, including the inactive human ADARs, regulate RNA editing through deaminase-independent mechanisms.

INTRODUCTION

RNA editing is a posttranscriptional process that introduces changes in RNA sequences and structures (Gott and Emeson, 2000). The most prevalent form of RNA editing in metazoa is the hydrolytic deamination of adenosine (A) to inosine (I) (Nishikura, 2010). Adenosine deaminases that act on RNA (ADARs) bind to double-stranded regions of RNA and catalyze this type of editing (Goodman et al., 2012; Savva et al., 2012). Although RNA editing was initially thought to be restricted to a few select mRNAs in the central nervous system, it is now clear that adenosine deamination is widespread, with current estimates of 400,000–1,000,000 A-to-I edits in the human transcriptome (Ramaswami et al., 2013).

Adenosine and inosine have different base-pairing properties; therefore, editing alters RNA structure. Furthermore, given that inosine is recognized as guanosine by cellular machinery, RNA editing can modify splice sites, alter the amino acid encoded by a codon, and redirect microRNAs (miRNAs) and small interfering RNAs (siRNAs) to new targets (Hundley and Bass, 2010; Rosenthal and Seeburg, 2012). Given that the extent of RNA editing varies during development and between cell types (Wahlstedt et al., 2009), this type of modification dynamically regulates gene expression (Tan et al., 2009).

The molecular diversity generated by ADARs is most pronounced in the brain transcriptome (Blow et al., 2004; Paul and Bass, 1998). Consistent with this, deletion of ADARs in lower organisms, such as C. elegans and Drosophila, results in behavioral defects (Palladino et al., 2000; Tonkin et al., 2002), indicating that RNA editing is required for proper neuronal function. Furthermore, alterations in editing levels have been observed in a number of neuropathological diseases, including epilepsy, depression, amyotrophic lateral sclerosis, and brain tumors (Farajollahi and Maas, 2010; Tariq and Jantsch, 2012).

In both development and disease, ADAR expression levels do not directly correlate with the extent of editing (Maas et al., 2001; Wahlstedt et al., 2009), implying that other mechanisms exist to regulate ADAR-mediated RNA editing. Both alternative splicing (Lai et al., 1997; Rueter et al., 1999) and posttranslational modification (Desterro et al., 2005) of ADARs generate less active variants of ADARs. Likewise, editing can be inhibited by...
sequestration of ADAR in the nucleolus (Sansam et al., 2003) or enhanced by proteins that promote nuclear localization of ADARs (Marcucci et al., 2011; Ohta et al., 2008). In addition to proteins that directly regulate ADARs, it has recently been demonstrated that both the local RNA structure (Daniel et al., 2012) and RNA binding protein (RBP) landscape of individual transcripts (Tariq et al., 2013) regulate ADAR activity. To date, none of these mechanisms have been linked to reduced RNA editing activity in disease (Orlandi et al., 2012). Furthermore, it is unlikely that regulators of specific transcripts will play a key role in the global hypoediting of transcripts observed in many human cancers and neurological diseases.

To identify mechanisms that could decrease global RNA editing levels, we focused on the role of catalytically inactive ADAR family members. The C. elegans genome encodes two proteins with the common ADAR family domain structure (ADR-1 and ADR-2). However, ADR-1 lacks several key amino acids required for deaminase activity. Worms lacking the adr-2 gene have no detectable editing of the six known edited endogenous mRNAs (Tonkin et al., 2002), suggesting that ADR-2 is the catalytically active ADAR protein in worms. However, initial studies of worms lacking adr-1 revealed alterations in the editing efficiency of all six endogenous mRNAs examined (Tonkin et al., 2002). In addition, recent deep sequencing of C. elegans small RNAs identified over 30 small RNAs that are edited in vivo, and each have altered editing levels in worms lacking adr-1 (Warf et al., 2012). These prior observations suggest ADR-1 regulates editing. However, it is also possible that background mutations in the strains lacking adr-1 contribute to alterations in editing or that loss of adr-1 indirectly affects editing by ADR-2. To directly address these concerns, we developed a quantitative assay to measure in vivo editing levels of worms expressing adr-1 transgenes. About 40% of adenosines within three known edited mRNAs were affected by loss of adr-1. Furthermore, using a combination of high-throughput RNA sequencing of transgenic worms and probabilistic modeling we were able to identify 48 edited transcripts and demonstrate that loss of adr-1 affects editing of at least half of these newly identified ADAR targets. Using an RNA immunoprecipitation (RIP) assay, we demonstrate that ADR-1 directly binds to known editing targets in vivo, that disrupting this binding alters editing of the mRNAs, and that ADR-1 and ADR-2 co-occupy transcripts in vivo. In summary, we demonstrate that catalytically inactive ADR-1 acts as a global regulator of editing by binding to target mRNAs and modulating the accessibility of ADR-2 for target adenosines.

RESULTS

ADAR-1 Significantly Alters RNA Editing of Multiple C. elegans mRNAs

To determine the ability of ADR-1 to directly regulate RNA editing in vivo, we established a quantitative assay to measure changes in editing in worms lacking adr-1 and then tested if these changes were rescued by an ADR-1 transgene. First, we examined editing levels at 50 individual adenosines within three known edited mRNAs: C35E7.6, lam-2, and pop-1. These three mRNAs were chosen based on their diverse cellular functions and length of the double-stranded 3’ UTR, which range from 517 to 1,423 nucleotides (nts). RNA was isolated from three independent biological replicates of wild-type and adr-1(–) adult worms. After reverse transcription, PCR amplification, and Sanger sequencing, editing efficiency was quantitatively measured using the Bio-Edit program. Technical replicates of the editing assay suggest that editing at each site can be determined with <1% error (Figure S1A), which is consistent with published data on the accuracy of measuring editing efficiency by Sanger sequencing (Eggington et al., 2011). Of the 50 edited adenosines, we observed statistically significant differences in editing levels between wild-type and adr-1(–) worms at 22 individual sites (Figure 1A). The bulk of the statistically significant sites (91%) had decreased editing, ranging from 3%–35%, in the absence of adr-1.

To demonstrate that these sites are directly regulated by ADR-1, a 3× FLAG-tagged genomic version of adr-1 was reintroduced to adr-1(–) worms by microinjection. Importantly, this transgenic worm rescues a known adr-1 dependent effect on neuronal protein expression (Hundley et al., 2008), indicating that the transgene expresses functional ADR-1 protein (Figure S1B). As the transgenic worms express FLAG-ADR-1 from an extrachromosomal array that is transmitted to progeny at a high frequency, but not 100%, a neuronal GFP marker was co-injected and flow cytometry was used to purify worms containing the ADR-1 transgene. In addition, to reduce effects of developmental timing on editing efficiency all worms were also sorted by size to obtain young adults. The quantitative editing assay showed that FLAG-ADR-1 significantly restored editing to 15 of the 22 editing sites altered in adr-1(–) worms (Figure 1B). It is important to note that editing changes in the FLAG-ADR-1 worms are not a general phenomenon, because editing sites that are not affected by loss of adr-1 are not altered by the transgene (Figure S1C). The 15 ADR-1-regulated sites include both adenosines that have increased and decreased editing in the absence of adr-1. Together, these data indicate that ADR-1 alters editing of multiple transcripts, but the effects vary depending upon the individual adenosines examined.

ADAR-1 Binds Directly to ADR-2 Target mRNAs In Vivo

Because the effects of adr-1 on editing are site specific, we hypothesized that ADR-1 is capable of regulating editing by utilizing two double-stranded RNA binding domains (dsRBDs) to bind to potential editing substrates and alter accessibility of ADR-2 to particular nucleotides. To determine if ADR-1 could bind ADR-2 editing targets in vivo, we developed an RNA immunoprecipitation (RIP) assay for ADR-1. Because a previously generated polyclonal antibody to ADR-1 was incapable of immunoprecipitating ADR-1 efficiently, the 3× FLAG-tagged ADR-1 transgenic worm was utilized. To measure specific binding of ADR-1 to target mRNAs in vivo, we compared immunoprecipitates (IPs) from FLAG-ADR-1 and adr-1(–) worms that were subjected to UV irradiation (Figure 2A). The IP samples were treated with Proteinase K to degrade FLAG-ADR-1 and release ADR-1-associated RNAs into the supernatant. RNA was extracted from the supernatant, reverse transcribed, and quantified using real-time PCR. Primers that amplify the three mRNAs tested in Figure 1 produced 3- to 15-fold more cDNA in the FLAG-ADR-1 IPs compared to adr-1(–) IPs (Figure 2B). In contrast, an mRNA that lacks double-stranded RNA (dsRNA),
gpd-3, is not enriched, indicating that, in vivo, ADR-1 specifically binds to these double-stranded ADR-2 target mRNAs. Because these three mRNAs have both adenosines that are inhibited and enhanced by ADR-1, these data support the hypothesis that ADR-1 modulates editing via a direct interaction with dsRNA. However, in order to regulate editing, ADR-1 needs to bind to the dsRNA before it is edited. To test this possibility, we performed the RIP assay in cells expressing FLAG-ADR-1, but lacking adr-2 and RNA editing. FLAG-ADR-1 was expressed and immunoprecipitated to a similar level in the presence and absence of adr-2 (Figure 2C). Compared to the adr-1(C0) worms, all three ADAR target mRNAs were enriched to a similar extent in the FLAG-ADR-1 IPs in the presence and absence of adr-2 (Figure 2D), indicating that binding of ADR-1 to known edited mRNAs is independent of ADR-2. Furthermore, because these mRNAs have no detectable editing in adr-2(C0) worms, we conclude that ADR-1 binds unedited mRNAs in the cell.

ADR-1 Alters RNA Editing via Binding to dsRNA In Vivo

Our results indicate that ADR-1 binds to mRNAs that are targets for editing by ADR-2 in vivo. To determine if this binding is required for the ability of ADR-1 to alter editing in vivo, we created mutations in the dsRBDs of ADR-1 and examined the effects on endogenous RNA editing. A patch of lysine (K) residues, referred to as the KKxxK motif (x = any amino acid), is required for dsRNA binding proteins to bind dsRNA (Ramos et al., 2000; Ryter and Schultz, 1998). Mutation of the lysines to glutamate (E) and alanine (A) disrupts binding of human ADARs to dsRNA (Valente and Nishikura, 2007). To disrupt ADR-1 dsRNA binding, the KKxxK motif was mutated to EAxxA within both dsRBDs (referred to as the ds1+2 mutant) (Figure 3A). Similar to the aforementioned wild-type ADR-1, the ds1+2 mutant was 3× FLAG tagged and expressed at the same level in the presence and absence of adr-2 (Figure 2D), indicating that binding of ADR-1 to known edited mRNAs is independent of ADR-2. Furthermore, because these mRNAs have no detectable editing in adr-2(−) worms, we conclude that ADR-1 binds unedited mRNAs in the cell.

Figure 1. ADR-1 Alters Editing at Specific Adenosines in Multiple mRNAs

(A and B) Editing levels at individual nucleotides within the 3' UTRs were measured for three biological replicates. Error bars represent SEM. Significant changes (p ≤ 0.05) in editing levels between (A) wild-type and adr-1(−) or (B) adr-1(−) and FLAG-ADR-1 are marked with an asterisk.
SNVs between the seq on RNA from variants (SNVs) were further addressed by performing RNA-Illumina’s iGenomes collection. Unannotated single-nucleotide sequence (WS220,ce10) (Figure 4A). To distinguish true RNA among the strains and the published C. elegans mutant of reads is associated with each predicted site. Empirically, we seq data, where a confidence value based on the number C. elegans were subtracted from all other RNA-seq data sets. A Bayesian specific RNA sequencing (RNA-seq) of RNA from wild-type (CEN2), of ADR-1 across the transcriptome, we conducted strand-spe- editing of specific adenosines in vivo. To understand the impact Our data indicate that ADR-1 binding to target mRNAs alters lam-2 15 sites that were identified as significantly regulated by ADR- lam-2, with the exception of nt 631 of lam-2 (Figure 3D). Thus, ADR-1 binding to target mRNAs is required both for its ability to promote and inhibit editing of known edited mRNAs in vivo. Binding of dsRNA by ADR-1 Regulates Editing across the Transcriptome

Our data indicate that ADR-1 binding to target mRNAs alters editing of specific adenosines in vivo. To understand the impact of ADR-1 across the transcriptome, we conducted strand-spe- cific RNA sequencing (RNA-seq) of RNA from wild-type (CEN2), aDR-1(-), aDR-2(-), FLAG-ADR-1, and FLAG-ADR-1 ds1+2 mutant adult worms and compared the nucleotide changes among the strains and the published C. elegans genomic sequence (WS220,ce10) (Figure 4A). To distinguish true RNA editing events from SNPs, we removed annotated SNPs using Illumina’s iGenomes collection. Unannotated single-nucleotide variants (SNVs) were further addressed by performing RNA-seq on RNA from aDR-1(-);aDR-2(-) worms and identifying all SNVs between the aDR-1(-);aDR-2(-) RNA (which lacks all A-to-I editing) and the C. elegans genome. These 118,651 SNVs were subtracted from all other RNA-seq data sets. A Bayesian “inverse probability model” was then adapted (Li et al., 2008) to identify high-confidence A-to-I editing sites from the RNA-seq data, where a confidence value based on the number of reads is associated with each predicted site. Empirically, we found that a confidence threshold of 0.995 produced the largest number of predicted sites in all strains: 59 sites in N2, 141 sites in aDR-1(-), 71 sites in FLAG-ADR-1, 102 sites in FLAG-ADR-1 ds1+2 mutant, while identifying the lowest number of edits in the aDR-2(-) strain (six sites) that we presumed represented false positives (Table S1).

Of the 270 unique high-confidence editing sites that were identified, but not present in aDR-2(-) worms (Table S1), 250 sites are editing events that occur within 48 different transcripts; the remaining 20 high-confidence sites were located within the previously identified ADAR targets C35E7.6, lam-2, and mcs-1 (Morse et al., 2002; Morse and Bass, 1999). The majority (96%) of these candidate editing events occur within noncoding regions of the genome (Figure 4B). Strikingly, the vast majority of editing events occurred in 3′ UTRs, consistent with the hypothesis that A-to-I editing controls gene expression by altering regulatory motifs in these regions. Interestingly, regions of the genome that encode for transposons were the second most highly identified (18%) category of editing events. In addition, we did identify 11 potential editing sites in coding regions of eight different mRNAs. As editing events in the coding region of C. elegans mRNAs had not previously been identified, this suggests that, similar to mammalian and Drosophila ADARs, C. elegans ADARs may also perform site selective editing in vivo.

Although ADARs target dsRNA of any sequence, the extent of editing at a particular site depends on the neighboring nucleo- tidies (Wahlstedt and Ohman, 2011). Using the Two Sample Logo software (Vacic et al., 2006), the 270 candidate editing sites had an overrepresentation of A both immediately 5′ and 3′ to the edited adenosine, whereas both G and C are underrepre- sented at the positions 5′ to the edited adenosine, and C is underrepresented 3′ to the edited adenosine (Figure 4C). Both
in vitro biochemical studies and transcriptome-wide RNA-seq data indicate that human ADARs have a similar 5’ preference. However human ADARs tend to favor a G at the 3’ position to the edited adenosine (Lehmann and Bass, 2000; Riedmann et al., 2008). It is important to note that because of overlapping specificities of mammalian ADARs, human transcriptome-wide data sets apply to editing by both human ADAR1 and ADAR2. However, because C. elegans ADR-2 is responsible for deamination of all of the sites, our data provide in vivo nucleotide preferences of a single ADAR acting primarily at noncoding regions.

To validate the potential editing sites, Sanger sequencing editing assays were performed for nine edited transcripts (Figure S2A). Importantly, 50 of the 53 predicted sites were verified by Sanger sequencing, suggesting the false discovery rate of the pipeline is approximately 5.7%. In addition to the 50 editing sites identified from the RNA-seq analysis, Sanger sequencing of these nine transcripts revealed 179 additional editing sites (Table S2), indicating that our probabilistic model is capable of identifying highly edited transcripts.

To determine if ADR-1 affected editing across the transcriptome, the editing efficiency of the 270 high-confidence editing sites was quantified using a Bayesian model. To ensure accurate quantification, we processed all the RNA-seq reads through the bioinformatics pipeline described above (Figure 4A), with one exception: read filter 5d was relaxed from requiring an edit site to be 25 nt from each end down to a less-stringent 5 nt and required a minimum of five reads for a site in a given strain. With these criteria, we were able to quantify editing of over 100 sites for each of the four strains, with any two strains having an overlap of between 72 and 105 editing sites (Figures S2B–S2E). At a 5% editing threshold to categorize our newly identified sites into ADR-1 and non-ADR-1 regulated (Table S3). As multiple RNA-seq studies have shown that determination of editing levels increases with read coverage (Bahn et al., 2012; Lee et al., 2013), it is important to note that similar results (>80% overlap) were obtained when we utilized read density to estimate the error of editing at each site (Table S3), suggesting that the editing percent thresholds for ADR-1-regulated and nonregulated sites are accurate. Comparison of editing levels at the 81 sites common between wild-type and ADR-1(−) RNA-seq data sets revealed that over half (56%) of the edited adenosines have altered editing levels when we utilized read density to estimate the error of editing at each site (Table S3), suggesting that the editing percent thresholds for ADR-1-regulated and nonregulated sites are accurate. Comparison of editing levels at the 81 sites common between wild-type and ADR-1(−) RNA-seq data sets revealed that over half (56%) of the edited adenosines have altered editing levels when we utilized read density to estimate the error of editing at each site (Table S3), suggesting that the editing percent thresholds for ADR-1-regulated and nonregulated sites are accurate. Comparison of editing levels at the 81 sites common between wild-type and ADR-1(−) RNA-seq data sets revealed that over half (56%) of the edited adenosines have altered editing levels when we utilized read density to estimate the error of editing at each site (Table S3), suggesting that the editing percent thresholds for ADR-1-regulated and nonregulated sites are accurate. Comparison of editing levels at the 81 sites common between wild-type and ADR-1(−) RNA-seq data sets revealed that over half (56%) of the edited adenosines have altered editing levels when we utilized read density to estimate the error of editing at each site (Table S3), suggesting that the editing percent thresholds for ADR-1regulated and nonregulated sites are accurate.
Sanger sequencing analysis of the 3’ UTRs of known ADAR targets (Figure 1A). In addition, at 38 of these ADR-1-regulated sites we were able to quantify editing levels for both the FLAG ADR-1 and FLAG-ADR-1 ds1+2 mutant RNA-seq data sets. Editing levels at 13 sites located within the 3’ UTRs of eight newly identified ADAR target mRNAs were dependent upon dsRNA binding by ADR-1 (Figure 4E). Together these transcriptome-wide studies indicate that ADR-1 regulates editing of specific adenosines within the 3’ UTRs of the majority of C. elegans edited mRNAs and dsRNA binding is required for this function.

**ADR-1 and ADR-2 Co-occupy Transcripts In Vivo**

At present, it is unclear how ADR-1 binding to mRNAs affects editing by ADR-2. It is possible that ADR-1 and ADR-2 heterodimerize in the cell to edit certain transcripts, whereas others are edited by ADR-2 alone. Alternatively, it is possible that ADR-1 and ADR-2 interact on the same transcripts but regulate editing in an adenosine-specific manner. To gain insight into these possibilities, we examined the wild-type and FLAG-ADR-1 RNA-seq data sets to determine whether editing at ADR-1-regulated adenosines occurred on the same reads as edited adenosines.
that are not affected by loss of adr-1. For most of the transcripts edited in the 3' UTR (9/12), editing was observed at both adenosines affected by adr-1 and nonregulated sites, within the same 75 nt read (Table S3).

To provide further evidence that ADR-1 and ADR-2 associate on common targets in vivo, we immunoprecipitated FLAG-ADR-1 and tested for the presence of ADR-2 with an ADR-2-specific antibody (Figure 4F). ADR-2 was present in IPs from FLAG-ADR-1 worms, but not FLAG-ADR-1 ds1+2 mutant or adr-1(–) worms (Figure 4G). Consistent with an RNA-dependent interaction of ADR-1 and ADR-2, IPs of wild-type ADR-1 treated with RNase also resulted in reduced ADR-2 coimmunoprecipitation (Figures S2J and S2K). Together, these data suggest that ADR-1 and ADR-2 interact on transcripts in vivo but are not likely to heterodimerize independent of target mRNAs.

**DISCUSSION**

In this study, we have demonstrated that *C. elegans* ADR-1 utilizes its dsRNA binding function to regulate A-to-I editing levels in vivo. Using a high-throughput RNA sequencing approach coupled to probabilistic modeling, we were able to expand the number of known ADAR target mRNAs 5-fold as well as provide transcriptome-wide evidence that ADR-1 is a catalytically inactive member of the ADAR family. Furthermore, using both our extensive Sanger sequencing analysis of ADAR targets and quantification of transcriptome-wide RNA-seq data, we demonstrate that ADR-1 regulates editing efficiency of specific adenosines within most ADAR target 3' UTRs.

We propose that ADR-1 regulates editing by binding to target mRNAs and altering accessibility of ADR-2 for specific adenosines. Multiple recent studies support the idea that the RNA binding protein (RBP) landscape of ADAR target mRNAs affects editing levels (Bhogal et al., 2011; Gamcarz et al., 2013; Tariq et al., 2013). However, in most of these studies, RNA binding by the regulators was not shown to be required for A-to-I regulatory activity, and these regulators were all single-stranded RBPs that altered editing of specific coding editing events. In contrast, we demonstrate that ADR-1 binds to several target mRNAs via its dsRBDS, and that this binding is required for regulation of editing. This dsRNA binding activity would allow ADR-1 to interact with nearly all the same targets as ADR-2, thus allowing it to serve a more global role in regulating editing within long double-stranded regions. Because dsRBDS are the second most abundant RNA recognition motif (Steffl et al., 2010), it is unlikely that this regulatory role is limited to *C. elegans* ADR-1. Consistent with this, 20% of our newly discovered edited transcripts overlap with recently identified targets of another dsRNA binding protein (dsRBP), *C. elegans* Staufen (LeGendre et al., 2013) (Table S1).

Our Sanger sequencing and transcriptome-wide analyses suggest that the regulatory role of ADR-1 is specific to certain adenosines (Figure 1A; Table S3). Although dsRBPs are generally presumed to lack sequence specificity (Tian et al., 2004), recent structural data suggest ADARs recognize specific nucleotides within dsRNA (Steffl et al., 2010). Our RIP assay indicates that ADR-1 binds to *lam-2* and *pop-1* mRNAs to a similar extent in the presence and absence of adr-2 (Figure 2D). Thus, at least for certain edited mRNAs, ADR-1 does not compete with ADR-2 for binding sites in vivo. Consistent with this, the majority of the ADR-1-regulated sites identified in both the RNA-seq data sets and Sanger analysis have enhanced editing in the presence of adr-1 (Figure 1A; Table S3), suggesting that ADR-1 functions primarily to promote ADR-2 editing, not compete with ADR-2 for target adenosines. Given that editing is not required for ADR-1 to bind these mRNAs, we postulate that, in vivo, ADR-1 first binds to target mRNAs and then either alters binding of ADR-2 to specific regions and/or regulates the catalytic activity of ADR-2. Interestingly, it was recently demonstrated that human ADAR1 binding to mRNAs creates binding sites for another RBP, HuR, which results in increased RNA stability of HuR-ADAR1 bound transcripts (Wang et al., 2013). Similar to human ADAR1-HuR, we detected an in vivo interaction between wild-type ADR-2 and ADR-1, but not the ADR-1 ds1+2 mutant, which is consistent with ADR-1 and ADR-2 interacting on target mRNA. Interestingly, it has previously been suggested that human ADAR homodimerization on dsRNA is required for efficient editing in vitro (Jaikaran et al., 2002). Although our evidence indicates that ADR-1 utilizes dsRNA binding to regulate editing, it is possible that this regulatory function is due to effects of ADR-1 on expression of other RBPs, which, in turn, alter ADR-2 accessibility to target mRNAs. Future work aimed at both identifying ADR-1 and ADR-2 binding sites on mRNAs in vivo and determining the impact of ADR-1 on ADR-2 editing activity in vitro will be needed to determine if there is a correlation between binding site specificity and regulation of specific sites.

In summary, our results indicate that ADR-1 utilizes dsRNA binding to regulate A-to-I editing across the *C. elegans* transcriptome. These studies not only suggest a potential biological function for the catalytically inactive ADARs present in humans, but also unveil a potential mechanism for other dsRBPs to regulate RNA editing levels.

**EXPERIMENTAL PROCEDURES**

**Maintenance of Worm Strains and Transgensics**

Worm strains were maintained by growth on NGM plates seeded with *Escherichia coli* OP50. A detailed description of the transgenic strains is given in the Supplemental Experimental Procedures.

**RNA Isolation and Editing Assays**

Total RNA was isolated using Trizol (Invitrogen). RNA was further treated with Turbo DNase (Ambion) and then isolated using the RNA Easy Extraction Bioinformatics Pipeline. Libraries were normalized to 2 nM for reverse transcription and PFX Platinum DNA Polymerase (Invitrogen) for PCR amplification with gene-specific primers (Table S4). PCR products were gel purified and subjected to Sanger sequencing. For all editing assays, negative controls were conducted without Thermoscript RT to ensure that all DNA subjected to sequencing resulted from cDNA amplification.

**Strand-Specific RNA Sequencing**

Strand-specific mRNA sequencing libraries were prepared as described previously (Parkhomchuk et al., 2009). Libraries were normalized to 2 nM and sequenced for SE76 cycles on either HiSeq2000 [adr-1(–);adr-2(–)] or Illumina GALL (all other strains).

**Bioinformatics Pipeline**

To achieve accurate identification of editing sites, we combined filters from existing pipelines (Chen, 2013; Lee et al., 2013; Levanon et al., 2004; Ramaswami...
et al., 2012) in a strand-specific manner. Accurate quantification was performed by extending the existing Bayesian method for genomic variant calling used in the 1000 Genomes project (Li et al., 2008) with a custom-designed prior on the editing percent (Figure S2I). In addition to leveraging established considerations with regards to read sequencing and alignment errors (Kleinman and Majewski, 2012; Lin et al., 2012; Pickrell et al., 2012), our approach benefits greatly from using the adr-1(−)/adr-2(−) strain as a powerful filter for unannotated variants. Detailed steps of the pipeline and Bayesian method for variant calling are described in the Supplemental Experimental Procedures.

RNA Immunoprecipitation Assay

After washing with IP buffer (50 mM HEPES [pH 7.4]; 70 mM K-Acetate, 5 mM Mg-Acetate, 0.05% NP-40, and 10% glycerol), worms were subjected to RNA Immunoprecipitation Assay. Detailed steps of the pipeline and Bayesian method for variant calling are described in the Supplemental Experimental Procedures.

Flow Cytometry

Flow cytometry was conducted at the IUB Flow Cytometry Facility by a dedicated technician using the COPAS Select (Union Biometrica) large particle sorter. Parameters were adjusted to select adult worms and expressing GFP for transgenic lines.

ACCESSION NUMBERS

Both the raw RNA sequencing data and the processed expression matrix are publicly available on NCBI Gene Expression Omnibus under accession number GSE51556.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, six figures, and four tables and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.2014.01.011.

ACKNOWLEDGMENTS

This work was supported by funds to H.A.H. from the Ralph W. and Grace M. Showalter Foundation and start-up from Indiana University School of Medicine, an NIH predoctoral training grant to M.C.W. (T32 GM007757), and NSF graduate research fellowship to B.K. and partially supported by grants from the National Institute of Health to G.W.Y. (R01 HG004659 and R01 NS075449). G.W.Y. is also supported as an Alfred P. Sloan Research Fellow. We thank Christine Hassel (IUB-Flow Cytometry) for assistance.

Received: October 17, 2013
Revised: December 19, 2013
Accepted: January 9, 2014
Published: February 6, 2014

REFERENCES


Paul, M.S., and Bass, B.L. (1998). Inosine exists in mRNA at tissue-specific levels and is most abundant in brain mRNA. EMBO J. 17, 1120–1127.


